Esmée Oussoren

1.2k total citations
32 papers, 768 citations indexed

About

Esmée Oussoren is a scholar working on Physiology, Molecular Biology and Clinical Biochemistry. According to data from OpenAlex, Esmée Oussoren has authored 32 papers receiving a total of 768 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Physiology, 9 papers in Molecular Biology and 9 papers in Clinical Biochemistry. Recurrent topics in Esmée Oussoren's work include Lysosomal Storage Disorders Research (18 papers), Metabolism and Genetic Disorders (9 papers) and Glycogen Storage Diseases and Myoclonus (8 papers). Esmée Oussoren is often cited by papers focused on Lysosomal Storage Disorders Research (18 papers), Metabolism and Genetic Disorders (9 papers) and Glycogen Storage Diseases and Myoclonus (8 papers). Esmée Oussoren collaborates with scholars based in Netherlands, United States and Germany. Esmée Oussoren's co-authors include Ans T. van der Ploeg, George J. G. Ruijter, Marion M. Brands, W.W.M. Pim Pijnappel, Arnold Reuser, Wim C.J. Hop, Frank Baas, P.A. Voûte, Erwin Pauws and Marjon van Groenigen and has published in prestigious journals such as Blood, PLoS ONE and Biochemical and Biophysical Research Communications.

In The Last Decade

Esmée Oussoren

32 papers receiving 752 citations

Peers

Esmée Oussoren
Comparison fields: 5 of 78
  • Physiology 383
  • Molecular Biology 245
  • Epidemiology 169
  • Rheumatology 166
  • Genetics 106
Shuan-Pei Lin Taiwan
Alexander Broomfield United Kingdom
Shu-Chuan Chiang Taiwan
Serena Gasperini Italy
C B Whitley United States
Ed Wraith United Kingdom
Ting‐Rong Hsu Taiwan
Norberto Guelbert Argentina
Fatih Süheyl Ezgü Türkiye
Nouriya Al‐Sannaa Saudi Arabia
Shuan-Pei Lin Taiwan View profile →
Citations per field, relative to Esmée Oussoren
Esmée Oussoren · 1×
Citations per year, relative to Esmée Oussoren
Esmée Oussoren · 1×

Countries citing papers authored by Esmée Oussoren

Since Specialization
Citations

This map shows the geographic impact of Esmée Oussoren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esmée Oussoren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esmée Oussoren more than expected).

Fields of papers citing papers by Esmée Oussoren

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esmée Oussoren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esmée Oussoren. The network helps show where Esmée Oussoren may publish in the future.

Co-authorship network of co-authors of Esmée Oussoren

This figure shows the co-authorship network connecting the top 25 collaborators of Esmée Oussoren. A scholar is included among the top collaborators of Esmée Oussoren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esmée Oussoren. Esmée Oussoren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Title Journal Authors Indexed citations
1 Social cognition, emotion regulation and social competence in classical galactosemia patients without intellectual disability Acta Neuropsychiatrica Gert J. Geurtsen, Carla E. M. Hollak et al. 1
2 Analysis of urinary oligosaccharide excretion patterns by UHPLC/HRAM mass spectrometry for screening of lysosomal storage disorders Journal of Inherited Metabolic Disease Marne C. Hagemeijer, Edwin H. Jacobs et al. 5
3 Modeling cartilage pathology in mucopolysaccharidosis VI using iPSCs reveals early dysregulation of chondrogenic and metabolic gene expression Frontiers in Bioengineering and Biotechnology Esmée Oussoren, Roberto Narcisi et al. 4
4 Effect of Anti-Iduronate 2-Sulfatase Antibodies in Patients with Mucopolysaccharidosis Type II Treated with Enzyme Replacement Therapy The Journal of Pediatrics Marianne Hoogeveen‐Westerveld, George J. G. Ruijter et al. 1
5 Mucolipidosis type II and type III: a systematic review of 843 published cases Genetics in Medicine Martina Wilke, Serwet Demirdas et al. 15
6 Using Out-of-Batch Reference Populations to Improve Untargeted Metabolomics for Screening Inborn Errors of Metabolism Metabolites Serwet Demirdas, Edwin H. Jacobs et al. 12
7 Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor Blood Saskia B. Wortmann, Johan L.K. Van Hove et al. 93
8 A Generic Assay to Detect Aberrant ARSB Splicing and mRNA Degradation for the Molecular Diagnosis of MPS VI Molecular Therapy — Methods & Clinical Development Esmée Oussoren, Atze J. Bergsma et al. 8
9 Classical galactosemia: neuropsychological and psychosocial functioning beyond intellectual abilities Orphanet Journal of Rare Diseases Kim J. Oostrom, Carla E. M. Hollak et al. 13
10 Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease Molecular Therapy — Methods & Clinical Development Esmée Oussoren, Ans T. van der Ploeg et al. 63
11 Hip disease in Mucopolysaccharidoses and Mucolipidoses: A review of mechanisms, interventions and future perspectives Bone Esmée Oussoren, Bianca Link et al. 10
12 Gray and white matter are both affected in classical galactosemia: An explorative study on the association between neuroimaging and clinical outcome Molecular Genetics and Metabolism Anouk Schrantee, Matthan W.A. Caan et al. 9
13 A long term follow-up study of the development of hip disease in Mucopolysaccharidosis type VI Molecular Genetics and Metabolism Esmée Oussoren, J. H. J. M. Bessems et al. 8
14 A Multiplex Assay for the Diagnosis of Mucopolysaccharidoses and Mucolipidoses PLoS ONE Eveline J. Langereis, Tom Wagemans et al. 30
15 Genetic basis of alpha‐aminoadipic and alpha‐ketoadipic aciduria Journal of Inherited Metabolic Disease Jacob Hagen, Heleen te Brinke et al. 44
16 Residual α-l-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients Molecular Genetics and Metabolism Esmée Oussoren, J. L. M. Keulemans et al. 40
17 Up to five years experience with 11 mucopolysaccharidosis type VI patients Molecular Genetics and Metabolism Marion M. Brands, Esmée Oussoren et al. 31
18 Mucopolysaccharidosis: Cardiologic features and effects of enzyme‐replacement therapy in 24 children with MPS I, II and VI Journal of Inherited Metabolic Disease Marion M. Brands, Ingrid M.E. Frohn-Mulder et al. 60
19 Bone, joint and tooth development in mucopolysaccharidoses: Relevance to therapeutic options Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease Esmée Oussoren, Marion M. Brands et al. 77
20 Molecular Cloning of Human MUC3 cDNA Reveals a Novel 59 Amino Acid Tandem Repeat Region Biochemical and Biophysical Research Communications B. Jan‐Willem van Klinken, Esmée Oussoren et al. 25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026